Patent 7179791 was granted and assigned to Duke University on February, 2007 by the United States Patent and Trademark Office.
Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.